CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor AgonistBERKELEY HEIGHTS, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world, today announced the successful completion of its Series D1 financing, raising up to $287 million in capital. Proceeds from the round are expected to support the advancement of CX11, a differentiated oral small molecule GLP-1 RA for obese and overweight patients currently being evaluated in a Phase 2 trial conducted by CORXEL in the United States and a Phase 3 trial conducted by Vincentage in China, and other cardiometabolic programs, including for acute ischemic stroke and hypertension.
Data from the Phase 2 Clinical Trial of CX11/VCT220 in China Presented at ADA 2025BERKELEY HEIGHTS, N.J. and SHANGHAI, June 23, 2025 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world, in collaboration with its partner, Chengdu Vincentage Pharma Co., Ltd. (Vincentage), announced the positive China Phase 2 clinical results for its oral small molecule once-daily glucagon-like peptide-1 receptor agonist (GLP-1 RA) CX11/VCT220, presented via poster presentation at the American Diabetes Association’s (ADA) 85th Scientific Sessions. The abstract will also be published online on the Diabetes® journal’s website.
CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight ConditionsBERKELEY HEIGHTS, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world, today announced the clearance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) for a U.S. Phase 2 trial of CX11, an investigational oral once-daily small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). This randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of CX11 in patients with obesity and overweight conditions in the U.S., with enrollment expected to begin in the second quarter of 2025.
